The CARMA study is evaluating ELC-301, an iTANK-armed CD20-targeting CAR T-cell therapy, in patients with relapsed or refractory B-cell lymphoma. The first dose cohort consisted of three patients treated with the lowest dose level, equivalent to one-tenth of the planned maximum dose.

“We are thrilled with the early results from the CARMA study, where ELC-301 has successfully cleared all active lymphoma in two out of three treated patients, including one who had previously failed CD19 CAR T-cell therapy. This was achieved despite using a low dose in a challenging patient population,” says Jamal El-Mosleh, CEO of Elicera Therapeutics. “These preliminary data, though from a small cohort, highlight the unique potential of our iTANK-armed CAR T-cell therapy and support our belief that ELC-301 may offer meaningful benefits where existing therapies fall short.”

The CARMA study is continuing with patient enrollment at escalating dose levels to further assess safety, tolerability, and preliminary efficacy. Cohort 2 has already been initiated, with two patients treated so far at a dose level that is three times higher than that of Cohort 1. Additional preliminary data from this and subsequent cohorts will be reported as the study progresses and in connection with presentation at scientific conferences.